In their new Forefront article, @MedlawDan and @DrSinhaEsq from @sjquinney and @SLU_HealthLaw argue that researchers and physician scientists who accept private funding from profit-motivated actors must take affirmative steps to ensure it does not compromise the integrity of

In their new Forefront article, Karen Handorf, @CMonahan10, and Kennah Watts from @Georgetown discuss how information disclosed under the “Patients Deserve Price Tags Act” will drive systemic change only to the extent that employers have enough leverage to force the big three

In their new Forefront article, Nathan Hostert, @RozMurray3, @CM_Whaley, and @efusebrown from @Brown_SPH discuss how, when implemented in state employee health plans, reference-based hospital price caps have the potential to save states money that can be reallocated to crucial

In an update to a 2020 Health Affairs article, J. Catherine Maclean and coauthors of @GeorgeMasonU, @RANDCorporation & @BrownUniversity estimate the effect of ACA Medicaid expansion on specialty SUD treatment episodes during the period 2010–22.

Elizabeth Stone and coauthors of @rutgersifh, @UPennDBEI, @BrownUnivHealth evaluate the impact of ACA Medicaid expansion on state-level pre-exposure prophylaxis (PrEP) prescribing outcomes from the period 2012–23. https://t.co/itfxQYecEB

In his new Forefront article, @joshliaotweets discusses how success in the Wasteful and Inappropriate Service Reduction (WISeR) model and any future expansions will hinge not only on the precepts of prior authorization but also on attention to underlying coverage variation,

In their new #Crossroads article, @jasonlevitis, @SabrinaCorlette, and Claire O’Brien of @urbaninstitute and @McCourtSchool discuss how, with 2026 rates already set and consumers starting to learn of premium increases, delays in extending the premium tax credit (PTC) enhancements

In their new Forefront article, Kristi Martin and Rachel Sachs of @CamberCollectiv and @WashU discuss the final guidance for the 2028 cycle of the Medicare drug price negotiation, which reflects CMS’s continued effort to balance statutory requirements with transparency,

In their new Forefront article, @NikkiRomanik and @KindrachukJason from @BrownUniversity and @umanitoba discuss how outbreaks of mpox have now been reported in more than a dozen countries across Africa, revealing a continent-wide surge just as the US and Europe dramatically scale

As featured in this month’s issue, Aditi Vasan and coauthors of @ChildrensPhila and @Penn examine the association between parents’ receipt of monthly expanded Child Tax Credit payments during pregnancy and infant birth outcomes in Pennsylvania.

In their new Forefront article, @RitchieCS, Bruce Leff, @OrlaSheehan3, @montysmith96, and Frank McStay from @AAHPM, @HopkinsMedicine, and @DukeMargolis discuss how understanding the needs of high-need, high-cost community-based beneficiaries, including homebound status, will help

In their new Forefront article, @MaraMcDermott, Will Robinson, and Kris Smith from @Acct4Health and @harmony_cares discuss how Medicare’s recent experience with skin substitutes demonstrates why the accountable care movement is important to stopping waste, fraud, and abuse.

In their new Forefront article, @a_rutschman and Jacqueline Penrod of @VillanovaU contrast the differences between the traditional model of vaccine federalism and the emerging paradigms introduced by the ongoing shifts in vaccine policy—and then consider the long-term

In their new @Health_Affairs paper, Jennifer Kao and coauthors of @uclaanderson, @cambridgelaw, @UCalgary, @HarvardMed & @DeptPopMed assess the impact of @US_FDA risk evaluation and mitigation strategy (REMS) programs on generic drug approvals.

How does immigration policy affect immigrant health, coverage and access & the health care economy? Learn more on Oct 15.

In his new Forefront article, @DrWmPadula from @USC discusses how switching to Medicare Advantage from fee-for-service (and vice versa) may ultimately restrict access to novel medications and therapies.

Our October 2025 issue is now available! This month’s issue features a range of topics, including vaccine economics, the role of private equity (PE) in health care, Medicare Advantage (MA), Medicaid, and more. https://t.co/833HDFoAfJ

How to make one line in the FDA Commissioner’s new drug review program into a force for affordable access for patients -- a new @Health_Affairs Scholar paper by ICER President and CEO Sarah Emond and Chief Scientific Officer Dan Ollendorf:

In their new Forefront article, Julia Burleson, @kfdavenport66, @RachelESwindle, and @CMonahan10 from @McCourtSchool discuss how, by quantifying the growth and distribution of outpatient facility fees, states such as Colorado, Maine, Connecticut, and Washington are providing a

In her new #Crossroads article, @Katie_Keith of @oneillinstitute discusses how additional federal restrictions on mifepristone—whether imposed by the courts or the Trump administration in the future—would dramatically reduce access in states where abortion remains lawful after